Diabetes: HOME reveals new data on a cornerstone of treatment.
A question often asked by health-care providers is whether metformin has added benefits if continued after patients with type 2 diabetes mellitus switch to insulin. Beneficial effects on macrovascular end points observed in response to sustained metformin therapy argue in favor of this approach, according to new research from The netherlands.
Cefalu
William T
WT
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use; D008687:Metformin / Q000627:therapeutic use; D016896:Treatment Outcome
D007004:Hypoglycemic Agents; D007328:Insulin; D008687:Metformin
Diabetes Care. 2009 Jan;32(1):193-203
18945920
Diabetes Care. 2002 Dec;25(12):2133-40
12453950
Lancet. 1998 Sep 12;352(9131):837-53
9742976
N Engl J Med. 2008 Jun 12;358(24):2545-59
18539917
Obesity (Silver Spring). 2008 Oct;16(10):2323-30
18719634
N Engl J Med. 2009 Jan 8;360(2):129-39
19092145
Nat Med. 2004 Apr;10(4):355-61
15057233
N Engl J Med. 2008 Jun 12;358(24):2560-72
18539916
Arch Intern Med. 2009 Mar 23;169(6):616-25
19307526